Trial Profile
AA Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Anticoagulants; Antiplatelets; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate; Rosuvastatin
- Indications Acute coronary syndromes; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms ODYSSEY J-IVUS
- Sponsors Sanofi
- 20 Aug 2019 Primary endpoint has been met. (Percent change in normalized total atheroma volume (TAV))
- 20 Aug 2019 Results published in the Circulation Journal
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.